Longitudinal trends in community-onset bacteraemia caused by ceftriaxone non-susceptible Escherichia coli, Proteus mirabilis, Klebsiella oxytoca, and Klebsiella pneumoniae (2016-2024)

2016-2024 年由头孢曲松不敏感的大肠杆菌、奇异变形杆菌、产酸克雷伯菌和肺炎克雷伯菌引起的社区获得性菌血症的纵向趋势

阅读:1

Abstract

BACKGROUND: The increasing prevalence of ESBL-producing Enterobacterales complicates treatment and worsens outcomes. However, contemporary data describing the prevalence and temporal trends in established risk factors for community-onset ceftriaxone non-susceptible (CRO-NS) bacteraemia remain limited. METHODS: This retrospective cohort study included adults with community-onset bacteraemia due to Escherichia coli, , Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis, evaluated at Phoebe Putney Health System (Albany, GA) between January 2016 and November 2024. Community-onset was defined by the first positive blood culture collected in the ER or ≤48 h of presentation. CRO susceptibility was determined by institutional antimicrobial susceptibility testing. Polymicrobial bacteraemia, incomplete records, or interfacility transfer were excluded. RESULTS: Among 1392 patients with community-onset bacteraemia, 127 (9.1%) were due to CRO-NS isolates, with E. coli accounting for 83%. The prevalence of CRO-NS isolates doubled over the study period, increasing from 7% in 2016 to 16% in 2024 (P = 0.008), reflecting an approximate annual increase of 1%. Most patients were older adults (median age 67), female (57%), and Black or African American (53%), with multiple comorbidities (median Charlson Comorbidity Index 5). A urinary source was most common (67%). Recent antibiotic use (≤30 days: 37%; ≤90 days: 61%) and prior hospitalization (≤90 days: 39%; ≤1 year: 61%) were frequent. Most established risk factors remained stable over time. CONCLUSION: Community-onset CRO-NS bacteraemia more than doubled over nine years, driven primarily by E. coli. These findings demonstrate the expanding burden of antimicrobial resistance in the community and emphasize the importance of local surveillance and risk-based empiric prescribing strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。